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Spontaneous canine simple mammary tumors (CMTs) are often viewed as models
of human breast cancer. Cancer-associated stroma (CAS) is central for initiation and
progression of human cancer, and is likely to play a key role in canine tumors as well.
Until recently, however, canine CAS in general, and in CMT in particular, lacked detailed
characterization and it remained unclear how canine and human CAS compare. This
void in knowledge regarding canine CAS and the resulting lack of unbiased cross-
species analysis of molecular homologies and differences undermined the validity of the
canine model for human disease. To assess stromal reprogramming in canine breast
tumors, we have recently established a protocol to specifically isolate and analyze CAS
and matched normal stroma from archival, formalin-fixed paraffin embedded (FFPE)
clinical tumor samples using laser-capture microdissection followed by next-generation
RNA-sequencing. Using this approach, we have analyzed stromal reprogramming
in both malignant canine mammary carcinomas (mCAs) as well as benign canine
mammary adenomas in a series of studies. Our results demonstrate strong stromal
reprogramming in CMTs and identify high-grade molecular homology between human
and canine CAS. Here, I aim to give a short background on the value of comparative
oncology in general, and spontaneous CMT in particular. This will be followed by a
concise review of the current knowledge of stromal reprogramming in both malignant
canine mCA and benign adenoma. Finally, I will conclude with insights on highly
conserved aspects of stromal reprogramming between CMT and human breast cancer
that accentuate the relevance of CAS in CMT as a model for the human disease.
Keywords: laser-capture microdissection, RNA sequencing, canine mammary carcinoma, canine mammary
adenoma, breast cancer, tumor stroma, tumor microenvironment, comparative oncology
INTRODUCTION
The majority of all cancers derive from corrupted epithelial cells that give rise to tumor
cells that disregard the tissue boundaries of their natural habitat. Yet, these epithelial tumor
cells are not living in an isolated environment, and – far from being self-sufficient – heavily
depend on their microenvironment for survival and growth (Hanahan and Coussens, 2012).
This microenvironment, also called cancer-associated stroma (CAS), consists of a heterogeneous
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mixture of different non-tumor cells (among them fibroblasts,
immune cells, vascular cells, adipocytes, and others), as well as
extracellular matrix (ECM). CAS has been abundantly shown to
play a key role in initiation and progression of a wide variety of
tumors, and its manifold roles in tumor biology have been widely
documented [e.g., reviewed in Bissell and Hines (2011); Bussard
et al. (2016), Hanahan and Coussens (2012); Kalluri (2016),
and Quail and Joyce (2013)]. Nevertheless, the field is still far
from completely understanding the mechanisms by which CAS
influences tumor biology, the molecular players that are involved,
and the intricacies of the cross-talk between CAS and tumor cells.
Due to the closely related pathophysiology, naturally
occurring cancers in the domestic dog are progressively leveraged
as a valuable source of information to better understand the
biology behind tumor development and possibly find novel
anti-cancer treatments (Karlsson and Lindblad-Toh, 2008;
Gardner et al., 2015; Rogers, 2015). While increasing efforts
have been focused on analysis of the molecular aspects of
tumor cells in canine cancers and their comparison with
aberrations in human tumor cells, canine CAS greatly lacks
characterization. Hence, it remains completely unclear how
canine and human CAS compare. Given the central importance
of CAS for the biology of human cancer, this striking shortage
of data on canine CAS and the resulting lack of unbiased
cross-species analysis of molecular homologies and differences
threaten to undermine the validity of the canine model
for human disease.
Among various other tumor types, naturally occurring canine
mammary tumors (CMTs) are viewed as excellent translational
model for human breast cancer. Recent work by my group
has begun to assess stromal reprogramming in spontaneous
CMTs by next-generation RNA-sequencing (RNAseq) in both
malignant canine mammary carcinomas (mCAs) and benign
canine mammary adenomas, and to probe the extent of
molecular homology between human and canine CAS. In the
following, I aim to give a short background on the value
of comparative oncology in general, and spontaneous CMT
in particular. This will be followed by a concise review of
the current knowledge of stromal reprogramming in both
malignant canine mCA as well as benign adenoma. Finally,
I will conclude with insights on highly conserved aspects of
stromal reprogramming between CMT and human breast cancer
that accentuate the relevance of CAS in CMT as a model for
the human disease.
NATURALLY OCCURRING TUMORS IN
DOGS AS TRANSLATIONAL MODELS
FOR HUMAN CANCER
A plethora of in vitro and in vivo models have been used over
the last century to gain insights into cancer biology. While
these models have undoubtedly been highly informative in many
aspects and lead to various scientific breakthroughs, the inherent
limit in most of the used models is their inability to fully replicate
the conditions and mirror the complexity of spontaneously
developing patient tumors (Karlsson and Lindblad-Toh, 2008;
Uva et al., 2009; Rowell et al., 2011; Liu et al., 2014; Schiffman
and Breen, 2015). The field of comparative oncology aims to
address these shortcomings by widening the research focus
from classical rodent models toward spontaneous tumors that
develop in other animals, such as the domestic dog. This
additional perspective is perceived as a chance to complement
and enhance our understanding of complex diseases, such as
cancer, as the comparison of tumor development and risk
factors across species provides the opportunity to discover basic
mechanisms of tumorigenesis (Karlsson and Lindblad-Toh, 2008;
Paoloni and Khanna, 2008; Gordon et al., 2009; Schiffman and
Breen, 2015). Due to the many similarities shared between
dogs and humans, the domestic dog is considered one of the
best examples for comparative oncology. Firstly, the number of
genes in dogs and humans are comparable, and evolutionarily
conserved alterations in the genome are shared between these
species (Bejerano et al., 2004; Karlsson and Lindblad-Toh, 2008;
Rivera and Euler von, 2011; Rowell et al., 2011; Schiffman and
Breen, 2015). Cancer in both species develops spontaneously
with similar pathophysiology, and often manifests in similar
clinical presentation and histology. As such, development of
spontaneous tumors in dogs has strong parallels with the natural
progression of cancer development in humans, and is considered
a better proxy of tumor biology than animal models with
induced tumorigenesis. The higher life expectancy compared to
rodent models and the same environmental factors that dogs
and humans are exposed to, combined with the fact that dogs
often receive a high level of healthcare, further strengthen the
value of comparatively analyzing canine and human cancers.
Also, as a result of inbreeding and high degrees of consanguinity,
certain breeds of dogs have been shown to carry genetic
predispositions for certain cancer types, facilitating the discovery
of risk alleles responsible for the disease [reviewed in Schiffman
and Breen (2015)]. Altogether, these insights emphasize the
potential of the dog as models for human cancer and offer
the possibility to overcome limits of xenograft and genetically
engineered rodent models leading to improved understanding
of tumor biology and biomarker discovery. The interested
reader is further referred for a more detailed discussion to
several excellent reviews on the subject (Rowell et al., 2011;
Schiffman and Breen, 2015).
CANINE MAMMARY TUMORS AS A
MODEL FOR HUMAN BREAST CANCER
Among many different cancer types, especially CMTs have
garnered attention as useful models for human breast cancer
(Sorenmo et al., 2009; Queiroga et al., 2011b; Abadie et al.,
2017; Nguyen et al., 2017). In relative terms with regards to life
expectancy (i.e., converting “dog years” into “human years”), the
age of onset is comparable between women and bitches. The
incidence of CMTs starts to increase after the age of 6 years
(the equivalent of age 40 years in humans) and peaks between
8 and 14 years (humans age 50–70 years) (Queiroga et al.,
2011b; Rowell et al., 2011; Bundesamt für Statistik, 2015; Bray
et al., 2018; World Health Organization, 2018). Furthermore,
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it is the most frequent cancer diagnosed both among female
dogs as well as women suffering from cancer (Sorenmo et al.,
2009; Lahkhani et al., 2012; Liu et al., 2014; Bray et al., 2018).
A retrospective study on canine tumors in Switzerland between
1955 and 2008 found that 20.5% of all canine tumors were located
in the mammary gland (Grüntzig et al., 2015). A retrospective
study in Italy between 1985 and 2002 even found 70% of all
tumors of female dogs to be located to the mammary gland
(Merlo et al., 2008). On a global level, CMTs occur in >40%
of female dogs and show and annual incidence rate varying
between 192 and 205/100,000 dogs, comparable to human data
with incidence rates of 125/100,000 women in the United States,
and 144/100,000 women in Switzerland (Queiroga et al., 2011b;
Sleeckx et al., 2011; Liu et al., 2014; Bundesamt für Statistik,
2015). Interestingly, CMT incidence is lower in the United States
than in other countries like Sweden, presumably because dogs
tend to get neutered at an early age in the United States and
therefore receive less gestagen preparations for heat prevention
(Sleeckx et al., 2011).
The anatomy of the normal mammary gland is similar in
dogs and women. The alveoli and ducts of the mammary gland
consist of luminal epithelial cells lined by myoepithelial cells
and are separated from the surrounding connective tissue by the
basement membrane (Liu et al., 2014; Santos and Matos, 2015).
In both species tumor formation is seen as a dynamic process
starting from benign hyperplastic lesions that can evolve into a
carcinoma in situ. In a further step, these tumors can become
invasive, which is marked by the disruption of the basement
membrane and potential seeding of metastases (Gilbertson et al.,
1983; Burstein et al., 2004; Simpson et al., 2005; Sorenmo et al.,
2009). On a molecular level, many of the key alterations in human
breast cancer are faithfully recapitulated in CMTs, including
germline mutations in BRCA1, BRCA2, and TP53 that are
associated with an enhanced risk of hereditary cancer in humans
(Liu et al., 2014; Matos and Santos, 2015; Santos and Matos, 2015;
Schiffman and Breen, 2015). And finally, besides clinical factors
such as tumor size, lymph node involvement, and clinical stage,
the prognostic value of histo-pathological aspects such as tumor
type and grade, and molecular subtypes (luminal A, luminal B,
HER2-enriched, and basal-like) is conserved between canine and
human breast cancer (Rivera et al., 2009; Queiroga et al., 2011b;
Sleeckx et al., 2011; Lahkhani et al., 2012; Rasotto et al., 2012,
2017; Im et al., 2013; Pena et al., 2013; Nguyen et al., 2017).
However, assessment of molecular subtypes is still limited to
research purposes and not routinely applied in CMTs (Sleeckx
et al., 2011; Rasotto et al., 2017).
Altogether, the similarities between CMTs and human breast
cancer suggest wide-ranging homologies in tumor biology.
Canine studies offer the opportunity to find novel biomarkers
not only for veterinary use, but also to benefit human
patients. Comparing the same disease in two different species
additionally helps differentiating the molecular “drivers” of the
disease from mere “passengers,” as key pathways should be
conserved between species. Finally, clinical trials in dogs can
be conducted in a shorter period than human studies, due to a
reduced lifespan and associated earlier manifestation of cancer
(Karlsson and Lindblad-Toh, 2008).
LARGELY UNCHARTED TERRITORY:
STROMAL REPROGRAMMING IN
CANINE MAMMARY TUMORS
While the importance of CAS in cancer initiation and
progression is becoming increasingly clear, data regarding
the molecular composition of CAS in canine cancer overall,
and CMTs in particular are sparse. Traditionally, analysis of
tumor samples by RT-qPCR or next-generation sequencing
approaches is performed in bulk. While highly informative,
the major drawback of bulk tissue analysis is the fact
that results reflect the mixture of all cells present in the
sample, not discriminating between epithelial cancer cells and
other non-neoplastic cells. The avoidance of inclusion of
samples “too rich in stroma” is usually attempted by setting
a cut-off value for stromal content as exclusion criterium.
Nevertheless, results from such bulk analyses clearly are a
conglomerate of highly varying amounts of different cell
populations present at sampling. Thus, this approach heavily
complicates the correct attribution of observed changes either
to the cancer cells or to the stromal cells. To date, most
studies investigating CMT on a molecular level, such as by
sequencing or microarray analysis, have analyzed tumor tissue
in bulk (e.g., Uva et al., 2009; Klopfleisch et al., 2010, 2011;
Liu et al., 2015; Bulkowska et al., 2017). Accordingly, specific
analysis of CAS in CMTs has thus far been restricted to
just single markers that were analyzed predominantly through
immunohistochemistry (IHC). CAS is composed of various
different cellular and extracellular components that have been
shown to exhibit strong influence on the hallmarks of tumor
cells (Hanahan and Coussens, 2012). Of these, in CMTs,
most attention has been focused on the roles of cancer-
associated fibroblasts (CAFs), a few components of the ECM,
a subset of infiltrating immune cells, as well as single markers
for angiogenesis. In the following, I will attempt to shortly
summarize the currently available data on the state of these
components in CAS of CMTs.
Cancer-Associated Fibroblasts and the
Extracellular Matrix
Cancer-associated fibroblasts are a heterogeneous population
of activated fibroblastic cells that present the most abundant
cell fraction in CAS and strongly influence tumor development
and progression (Chen and Song, 2019). CAFs often stain
positively for alpha smooth muscle actin (αSMA), a marker
for myofibroblast activation, and αSMA expression has been
associated with reactive tumor stroma in human breast
cancer and other tumors. As such, upregulation of αSMA
is often used as marker for CAS, and enhanced expression
of αSMA in human breast cancer is associated with poor
prognosis (Sappino et al., 1988; Elenbaas and Weinberg, 2001;
Yazhou et al., 2004; Surowiak et al., 2006, 2007; Yamashita
et al., 2012). In CMTs, αSMA-positive myofibroblasts have
been detected in CAS of adenomas and carcinomas, but
not in normal breast tissue, increasing in abundance with
higher tumor grade and histopathological signs of invasion
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and metastasis, and significantly related to poor prognosis
(Yoshimura et al., 2011).
The main function of fibroblasts is to maintain the integrity
of the ECM as structural support for cells and organs. As
activated fibroblasts, CAFs strongly influence CAS composition
and architecture through production and remodeling of ECM.
Changes in collagen density and fiber organization have been
associated with tumor grade and overall survival in CMTs
(Case et al., 2017). Expression of the ECM molecule Tenascin-
C (Tn-C), most likely produced by myofibroblasts, increased
from benign adenomas to malignant carcinomas, and with signs
of invasion and metastasis (Faustino et al., 2002; Yoshimura
et al., 2011, 2014). Versican is another component of the ECM
whose expression has been found to increase with malignancy
and invasiveness of the tumor cells (Damasceno et al., 2016).
Interestingly, the stroma of malignant tumors has been described
to increasingly express the known multidrug resistance-causing
transporters P-glycoprotein (PGP) and breast cancer resistance
protein (BCRP), suggesting a role for the tumor stroma in
the development therapeutic resistance (Levi et al., 2016).
The most thoroughly investigated ECM-remodeling enzymes
in CMTs belong to the group of ECM-degrading proteases
including matrix metalloproteinases (MMPs) and urokinase-
type plasminogen activator (uPA) and their inhibitors. These
play a key role in ECM homeostasis in human breast cancer
(Chen and Song, 2019). In CMTs, MMP2, MMP9, MMP14,
and uPA levels increase from healthy tissue to benign to
malignant CMTs, and are associated with increasing histological
grade, signs of invasion, and early death from CMT, and
present good prognostic factors (Papparella et al., 1997, 2002;
Yokota et al., 2001; Hirayama et al., 2002; Kawai et al.,
2006; Vinothini et al., 2009; Aresu et al., 2011; Lamp et al.,
2011; Santos et al., 2011b, 2012, 2013; Santos and Matos,
2015). Unfortunately it is not always clear where exactly these
MMPs were expressed, as some of the analyses were performed
on bulk tumor tissue. Nevertheless, it is evident that MMP
activity is mainly focused on the ECM, and a subset of
these studies detected their expression also in fibroblasts close
to the invasive tumor cells. Interestingly, MMP13 expression
decreased significantly between benign and malignant CMT
(Aresu et al., 2011).
The picture is slightly less clear for the MMP inhibitors: most
reports have found TIMPs 1-3 and RECK to be highly expressed
in malignant carcinomas (Papparella et al., 1997; Yokota et al.,
2001; Hirayama et al., 2002; Kawai et al., 2006; Santos et al.,
2011a). One report found expression of TIMP-2 to decrease in
tumor tissue compared to controls, and also to decrease from
grade I to grade III tumors (Vinothini et al., 2009), while Aresu
et al. (2011) did not find statistically significant differences in
TIMP-2 (nor TIMP-1, TIMP-3, or RECK) levels between benign
and malignant tumors.
In summary, understanding of fibroblast activation and
ECM remodeling in CMTs has thus far mainly focused
on αSMA-positive myofibroblasts, and expression of Tn-
C, MMPs, and their inhibitors. While these analyses have
yielded interesting data also regarding similarities to CAS in
human breast cancer, the understanding of both fibroblast
activation and ECM remodeling in CMT remains extremely
limited to date.
Infiltrating Immune Cells
Infiltration of immune cells into tumors has been a longstanding
area of interest in tumor biology, and the cellular composition
of the immune infiltrate is clearly linked to disease outcome
in CMTs (Gilbertson et al., 1983; MacEwen, 1990; Kim et al.,
2013). High levels of CD4+ and CD3+ T-cells have been
associated with metastasizing tumors and shorter overall survival
(Estrela-Lima et al., 2010; Saeki et al., 2012; Carvalho et al.,
2015a,b, 2016b). More detailed assessment of the localization
of immune infiltrates with respect to the tumor cells found
that tumor-infiltrating CD3+ T-lymphocytes were significantly
more frequent in benign than malignant tumors, and conversely,
peripheral CD3+ cells were more frequent in malignant than
benign tumors (Carvalho et al., 2011). Furthermore, high number
of neutrophils were associated with aggressive CMTs, while
in contrast high amounts of plasma cells, macrophages, and
CD8+ T-cells, together with low numbers of CD4+ T-cells,
were associated with less aggressive tumors (de Souza et al.,
2018). Taken together, these results suggest a strong role for
T-lymphocytes in progression of CMTs, and also highlight that
it is important to assess not only abundance of immune cells,
but also identify their subtypes and define their exact localization
within the tumor, as infiltrating immune cells that shielded
from reaching the tumor cells cannot achieve immune control,
and might really do more damage by fueling tumor-promoting
inflammation instead. This is in line with current concepts
of immunologically hot vs. cold tumors in humans (Galon
and Bruni, 2019). Accordingly, presence of Foxp3+ regulatory
T-cells (T-regs) and myeloid-derived suppressor cells (MDSCs)
positively correlated with adverse prognostic factors, such as high
histological grade, lymphatic invasion, and metastasis (Król et al.,
2011a; Kim et al., 2012; Carvalho et al., 2016a; Mucha et al.,
2016; Sakai et al., 2018). These findings support the concept
that immune suppression through T-regs and MDSCs might
contribute significantly to CMT progression.
Several studies have shown a strong correlation between high
levels of tumor-associated macrophages (TAMs) and indicators
of malignancy, metastasis, as well as worse overall survival in
CMT (Restucci et al., 2002; Król et al., 2011b; Raposo et al., 2012,
2013; Lim et al., 2015; Carvalho et al., 2016b; Reis dos et al., 2019).
All of these studies detected TAMs based on IHC detection of
MAC387, but unfortunately did not attempt further subtyping
of the macrophages into (antitumoral) M1 or (pro-tumorigenic)
M2 phenotype. More detailed data regarding M1/M2 polarization
of TAMs in CMT have been recently emerging, demonstrating
significantly higher numbers of M2-TAMs in malignant CMTs
while benign tumors harbored M1-TAMs, suggesting a M1-to-
M2 shift of TAMs in malignant CMTs (Monteiro et al., 2018;
Seung et al., 2018). While these results are highly interesting,
there remains some controversy regarding whether CD204
represents a useful IHC marker for M2-polarized macrophages
in dogs that awaits clarification (Belluco, 2018).
In summary, striking parallels between canine and human
CAS with respect to the effect of the type of immune cell
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that strongly determines the effect on tumor progression are
beginning to emerge. The interested reader wishing to further
extend on parallels of CMT with human breast cancer in terms
of tumor-associated inflammation is referred to a recent review
on the topic (Carvalho et al., 2016c). Despite this progress, the
field is still far from a complete understanding of the effects of
different immune cells on the clinical course and prognosis of the
disease and more detailed insights are needed to further clarify
many of the outstanding questions. Further detailed insights into
immune components in CAS of CMTs, ideally also with regards
to molecular subtypes, are highly anticipated.
Angiogenesis
Sustained angiogenesis represents one of the core hallmarks
of cancer (Hanahan and Weinberg, 2011). A series of studies
has assessed the contribution of blood vessel supply to the
biology of CMTs. Indeed, in analogy to human breast cancer,
increased microvessel density (MVD) correlated with malignancy
and metastasis (Graham and Myers, 1999; Restucci et al., 2000;
Millanta et al., 2006; Lavalle et al., 2009; Al-Dissi et al., 2010;
Queiroga et al., 2011a; Carvalho et al., 2013; Sleeckx et al., 2014;
Diessler et al., 2016; Anjos Dos et al., 2019).
A plethora of different molecules are involved in controlling
the rate and extent of angiogenesis. Among the best studied ones
are vascular endothelial growth factors (VEGFs) that regulate
formation, function, and maintenance of vasculature (Simons
et al., 2016). In most studies, VEGF expression in CMT has been
closely correlated with metastasis to lymph nodes, clinical stage,
tumor grade, and malignancy (Qiu et al., 2008; Vinothini et al.,
2009; Clemente et al., 2010, 2013; Millanta et al., 2010; Klopfleisch
et al., 2011; Queiroga et al., 2011a; Carvalho et al., 2015a, 2016b;
Moschetta et al., 2015; Mucha et al., 2016). However, a few
reports have failed to see such an association (Millanta et al.,
2006; Santos et al., 2010, 2014). Unfortunately, most of these
studies have not differentiated between VEGF isoforms, which
would be an interesting additional information. Interestingly,
there is evidence for a strong link between immune cells, such
as TAMs, CD3+ T-cells, FoxP3+ T-regs, and mast cells, and
VEGF expression with increasing malignancy, suggesting that
immune cells influence tumor angiogenesis through secretion
of VEGF (Restucci et al., 2002; Im et al., 2011; Raposo
et al., 2013; Carvalho et al., 2015a, 2016a). Likewise, expression
of VEGFR-2, the main signaling VEGF receptor in vascular
endothelial cells, in endothelial cells within the tumor tissue
increased with malignancy, histological grade, and lymph node
metastases, implicating VEGF and VEGFR-2 in angiogenesis in
CMTs (Restucci et al., 2004; Diessler et al., 2016; Anjos Dos
et al., 2019). One study failed to find a connection between
VEGFR-2 expression and histologic grade (Al-Dissi et al.,
2010). Interestingly, a positive association between expression
of VEGFR-2 and stromal MMP9 has been described, indicating
a link between ECM remodeling and endothelial cell activation
(Santos et al., 2014).
While expanding our understanding of CAS in CMTs, all these
studies have only investigated a very limited number of targets,
mostly due to methodological limitations. When information is
available as to whether a molecule is expressed in the tumor
cells or rather one of the stromal components, it has been
mostly obtained through IHC analysis, whereas other approaches
have relied on bulk tumor analysis. A major draw-back of the
targeted analyses is that one can only analyze targets that are
known a priori, which precludes unbiased identification of novel
molecules of interest. Furthermore, the limited number of targets
that can be interrogated through most of these approaches makes
it impossible to gain a more wide-angled perspective of changes
in molecular networks underlying stromal reprogramming in
CMTs. As a direct consequence, unbiased cross-species analyses
of molecular homologies and differences in CAS between species
have therefore been precluded to date. Due to these limitations, it
remains largely unknown to what extent stromal reprogramming
in canine and human breast cancer are comparable, and what the
molecular similarities and differences are. A better understanding
of the biology of CAS in canine breast cancer is imperative to
both understand how CAS influences growth and progression of
CMTs as well as understand whether canine breast cancer really
is comparable to the human disease in all of its aspects.
TOWARD A MORE COMPREHENSIVE
PICTURE OF STROMAL
REPROGRAMMING IN CMTs
Driven by the lack of detailed characterization of stromal
reprogramming in CMTs caused by technical limitations
described above, we established a workflow to isolate subsections
of formalin-fixed paraffin-embedded clinical tumor samples
by laser-capture microdissection, and analyze gene-expression
changes therein. In a first study, we isolated CAS and matched
“normal” stroma (i.e., stroma isolated adjacent to unaltered
mammary glands) from FFPE specimen of 13 cases of canine
simple mCA, and analyzed the expression of seven well-described
CAS-markers in human mCA (PDGFRβ, MMP2, Col1α1, FAP,
ACTA2/αSMA, CXCL12/SDF1, and IL6) by RT-qPCR (Ettlin
et al., 2017). Our results demonstrated that ACTA2, COL1A1,
and FAP were upregulated in canine CAS, while PDGFRB,
MMP2, and IL6 expression did not significantly change between
normal stroma and CAS. CXCL12 expression was downregulated
in CAS compared to normal stroma. IHC validation of these
results revealed upregulation of αSMA, FAP, PDGFRB, and Cav-
1, while SDF1, MMP2, and FGF2 expression did not change.
These findings not only suggested the presence of molecular
similarities in CAS biology between canine and human mCA,
but also revealed some differences. While interesting, this RT-
qPCR-based approach had two major limitations: (i) the targets
of interest have to be defined a priori, which precludes an
unbiased analysis of the samples, and (ii) to the small amount
of RNA that can be extracted from small LCM-subsections of
FFPE strongly limits the number of RT-qPCR reactions that
can be run, thus strongly restricting the number of targets that
can be analyzed per sample. To overcome these problems, we
further optimized the RNA extraction protocol for the LCM
samples of FFPE tissue in a way that increased the average yield
per sample between 8- and 12-fold and allowed us to perform
next-generation RNAseq (Amini et al., 2017). An overview of
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the entire workflow is depicted in Figure 1. Thus far, we have
successfully applied this novel approach to analyze stromal
reprogramming in several different cohorts of clinical samples,
including malignant canine mCA and benign canine mammary
adenomas. In the following, I will shortly summarize the main
findings from these analyses.
Stromal Reprogramming in Canine
Simple Mammary Carcinoma
To begin to understand stromal reprogramming in canine simple
mCA on a transcriptome-wide scale, we analyzed matched CAS
and normal stroma from 15 clinical cases using our LCM-
RNAseq pipeline (Amini et al., 2019a). Strikingly, differential
gene expression changes clearly differed between normal stroma
and CAS, with 884 significantly deregulated genes. Strongest
changes were found in the genes involved in the immune
system, cell adhesion and differentiation, ECM organization,
and angiogenesis. Clearly, all of these processes are strongly
associated with stromal biology, further validating our analytical
approach. Unsupervised clustering of samples based on the
landscape of immune and stromal cells present in the samples
again clearly separated CAS and normal stroma, and revealed
strong increases in mesenchymal stem cells, gamma delta T-cells,
macrophages, plasmoid dendritic cells, and natural killer T-cells
in CAS. These results provide evidence for wide-ranging stromal
reprogramming in canine mCA, enabling for the first time a
detailed molecular analysis of CAS in canine mCA. We envisage
these data to significantly support the understanding of the
biology of canine mCA.
FIGURE 1 | Workflow to isolate and analyze areas of interest from FFPE tissue
specimens. After selection of appropriate FFPE specimen, tissue is cut into
10 µm sections and mounted on PEN membrane glass slides (Ettlin et al.,
2017). Slides are deparaffinized and stained using Cresyl Fast Violet (Amini
et al., 2017), followed by LCM to isolate areas of interest (e.g., CAS).
Whenever possible, matched control tissue (e.g., normal stroma) is isolated
from the same section to minimize differences in sample processing. RNA
isolation is performed using a sonication-based protocol combined with
protease digestion (Amini et al., 2017), followed by RNA quality control.
Analysis of isolated RNA can be performed by RNAseq [routinely using 4 ng
RNA as input per run (Amini et al., 2019a)], by RT-qPCR (Ettlin et al., 2017),
and possibly other applications that allow RNA analysis.
Stromal Reprogramming in Canine
Simple Mammary Adenoma
While canine simple mCAs are classified as malignant epithelial
neoplasms that infiltrate the surrounding tissue, canine simple
mammary adenomas represent benign, well-demarcated, and
non-infiltrative tumors that generally contain only very little
fibrovascular supporting stroma (Goldschmidt et al., 2011). To
date, it remains unclear whether and to what extent stromal
reprogramming occurs in these naturally occurring benign
tumors of the mammary gland. In fact, stromal reprogramming
in human breast cancer has been studied during progression from
in situ to invasive human mCA, in pregnancy-associated breast
cancer, in response to therapeutic radiation, and in inflammatory
breast cancer (Finak et al., 2006, 2008; Boersma et al., 2007; Casey
et al., 2008; Ma et al., 2009; Westbury et al., 2009; Planche et al.,
2011; Knudsen et al., 2012; Vargas et al., 2012; Harvell et al., 2013).
However, we are not aware of any published dataset regarding
stromal reprogramming in naturally occurring benign tumors
of the mammary gland. Since CAS has been shown to have
important roles in determining the growth and progression of
different tumor types, we hypothesized that differences in stromal
reprogramming between benign adenomas and malignant mCA
could contribute to the clinical behavior of these two tumor types.
To begin to understand stromal reprogramming in naturally
occurring benign tumors, we thus applied our approach to
isolate and analyze CAS and normal stroma from FFPE tissue
sections to 13 cases of canine simple mammary adenoma (Amini
et al., 2019b). We observed clear separation of normal stroma
and CAS samples, and identified 193 genes to be significantly
deregulated between the two entities. The strongest changes
occurred in processes related to cell adhesion, immune system,
proliferation and growth, differentiation, and ECM and collagen
organization. Hence, these results demonstrate that substantial
stromal reprogramming occurs also in small, benign tumors of
the mammary gland.
Having previously characterized stromal reprogramming in
canine mCA, we then sought to understand commonalities and
differences in stromal reprogramming between benign mammary
adenomas and malignant mCA. Our analyses showed that CAS
in benign adenomas is clearly distinct from malignant mCA.
Furthermore, adenoma-derived stroma was much more similar
to normal stroma than CAS from mCA, suggesting gradual
changes from normal to benign to malignant CAS to occur during
the development of tumors. Nevertheless, we also identified
commonly regulated genes in CAS of both benign and malignant
tumors. This comparative dataset allowed us to interrogate for
the first time the transcriptional levels of targets that have
been implicated in stromal reprogramming of canine breast
tumors thus far (see the sections “Cancer-Associated Fibroblasts
and the Extracellular Matrix,” “Infiltrating Immune Cells,” and
“Angiogenesis” for details). Figure 2 intends to give a schematic
overview of changes in mRNA abundance of these targets
between normal stroma, CAS in adenoma, and CAS in carcinoma
as detected by our RNAseq approach (Amini et al., 2019b).
These data give rise to several interesting observations: (i) some
targets, such as αSMA, Tn-C, and VEGFA, show changes in
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FIGURE 2 | Overview of transcriptomic changes in selected markers during
stromal reprogramming in canine mammary adenomas and carcinomas.
Schematic overview of transcriptomic changes of selected CAS-related
markers based on our transcriptomic analyses of normal stroma, CAS from
adenoma, and CAS from carcinoma isolated from canine breast tumor
specimens (Amini et al., 2019b). Protein names on the left are targets whose
expression in canine tumors has been investigated on protein level mostly by
IHC (for details and references, see the main text). The bars next to the protein
names indicate changes in RNA abundance of the respective targets between
stroma from normal glands (left), stroma from adenomas (middle), and
stroma from carcinomas (right), as detected by LCM-RNAseq. Targets
associated with fibroblast activation and remodeling of extracellular matrix are
depicted in blue, markers of immune cells are colored in green, and targets
involved in angiogenesis are shown in purple.
mRNA levels that mirror closely results obtained on protein level,
with increasing abundance from normal stroma to adenoma to
carcinoma; (ii) a number of targets whose expression has been
positively correlated with increasing malignancy (e.g., versican,
MMP9, and MMP14) show no changes in stromal mRNA
abundance between the three entities; (iii) there are some genes
whose expression is opposite of what would be expected from
literature regarding protein levels (e.g., MMP2, MMP13, TIMP3,
and VEGFR2); and (iv) one of the advantages of RNAseq-based
analysis is differentiation between closely related isoforms, e.g.,
changes in VEGF that are very specific to the different isoforms
of the protein. Differences in mRNA versus protein levels can be
explained by two different mechanisms: either the main source
of the protein in question is not the stroma itself, but rather the
tumor cells which release the product into their surroundings.
Or, if indeed it is produced by stromal cells, the increase in
protein production is due to post-transcriptional regulatory
mechanisms that do not impinge on mRNA transcription. To
further clarify these aspects, it would be interesting to compare
RNAseq data from the tumor cells to that of the respective stroma,
or to analyze the different tumor compartments using proteomic
analysis pipelines.
Highly Conserved Stromal
Reprogramming Between Canine and
Human Mammary Carcinoma
Our next aim was to understand to what extent stromal
reprogramming in canine and human mCA is comparable. We
reasoned that if stromal reprogramming in the two species shared
high levels of homology, this should result in a similar expression
pattern of differentially regulated genes between normal stroma
and CAS in both. We assessed this using several different
approaches. Firstly, juxtaposition of our canine CAS dataset to
a similar human dataset revealed that genes upregulated in the
canine dataset were on average also upregulated in the human
dataset, and likewise genes downregulated in the canine dataset
were also downregulated in the human dataset. Secondly, we
ranked the samples in the TCGA breast cancer subset (that
contains >1000 human tumor samples) according to stromal
enrichment scores (i.e., according to how much stroma they
contain) to compare our canine-derived stromal signature with.
By doing so, we found the canine-derived stromal signature to
be highly positively correlated with the enrichment of human-
derived stromal signature of the TCGA breast cancer subset.
The commonly perturbed pathways between canine and human
CAS included angiogenesis, epithelial mesenchymal transition,
glycolysis, pathways involved immune response, and others.
And finally, we demonstrated that the high level of molecular
homology between canine and human stromal reprogramming
manifested in a prognostic value of the canine CAS signature,
with upregulated genes in canine CAS highly enriched among
adversely prognostic genes in humans, and upregulated genes
in canine normal stroma highly enriched among favorably
prognostic genes in humans. In conclusion, these results clearly
demonstrated that stromal reprogramming in canine and human
mCA shares significant molecular homology. This homology
derives from conservation of key signaling pathways which
underlie the prognostic value of stromal gene expression changes
in both canine and human mCA. Hence, these findings clearly
emphasize the value of canine mCA as a model for human mCA.
CONCLUSION AND OUTLOOK
Increased understanding of stromal reprogramming in tumors
requires the ability to selectively analyze patient-derived CAS,
ideally using untargeted methods, such as RNAseq. To date,
stromal reprogramming has been mostly investigated using laser-
capture microdissection of fresh-frozen tissue, coupled with
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microarrays or sequencing approaches. However, use of fresh-
frozen tissues most often necessitate establishing prospective
trials to collect samples accordingly, requiring a high grade
of coordination between surgical resection and analysis, and
introducing temporal until all required cases are collected. More
importantly, it also precludes the analysis of archival FFPE
samples, which are the standard product of any pathology
department and can be kept at room temperature over long
periods of time. To circumvent these problems, we have
developed a protocol that allows the analysis of subsections of
FFPE patient samples by RNAseq, and have demonstrated its
feasibility and usefulness by analysis of stromal reprogramming
in several cohorts of patient samples. Importantly, the protocol
can be adapted to interrogate transcriptional reprogramming of
any area of interest in any type of tissue of any organism, provided
that the area is sufficiently large to be isolated and contains
sufficient RNA. Hence, we hope our approach to enable a wide
range of projects to understand transcriptional reprogramming
within distinct compartments of entire tissues. Over the last few
years, technological advances have made it possible to analyze
tumor (and other) tissues on the cellular level by single-cell
RNAseq. This presents a tremendous advance in analytic power
and novel insights. However, single-cell RNAseq can only be
performed on fresh tissue, which again precludes its applicability
for analysis of archival FFPE tissue. Also, the currently available
methodology is no accurate enough yet to be routinely used
in clinics. Furthermore, it requires sometimes lengthy digestion
steps to dissociate tissues into single cells that quite possibly also
introduce a fair amount of gene expression changes during the
preparation. Finally, the cost of single-cell RNAseq experiments
still is substantially higher than that of “canonical” RNAseq
analyses. Due to all these aspects, analysis of tissue subsections
of FFPE tissues using our LCM-RNAseq approach presents a
complementary approach of great value to further understand
transcriptional changes in defined locations of clinical specimen.
Despite the advances in analysis of stromal reprogramming
that occurs in human tumor samples, the study of CAS in
canine tumors has strongly lagged behind. Although a subset of
molecular and cellular aspects have been relatively well studied
in CMTs, the field is still far from having a more wide-angled
overview of stromal reprogramming that occurs in these tumors.
For the first time, our studies have started to shed light into
stromal reprogramming in canine simple mCA and canine simple
mammary adenoma, and begun to analyze the extent to which
CAS in canine mCA and human mCA compare. Our data show
wide-ranging stromal reprogramming in both canine mCA and
adenoma, and also reveal strong molecular homologies between
stromal reprogramming in human and canine tumors. Further
in-depth analysis of these data have the potential to significantly
increase our understanding of stromal reprogramming in canine
mCA, and also to identify the conserved aspects between species
that are likely drivers of the disease. Better understanding of
the molecular underpinnings of canine and human CAS holds
enormous potential for further interesting findings.
AUTHOR CONTRIBUTIONS
The author designed and wrote the entire manuscript
without external help.
FUNDING
Work in the author’s laboratory was financially supported by
the A.+S. Huggenberger Stiftung, the Heuberger Stiftung, the
Forschungskredit of the University of Zurich, the Promedica
Stiftung Chur, the Kurt und Senta Herrmann Stiftung, and the
Sassella Stiftung.
ACKNOWLEDGMENTS
The author thanks Dr. Parisa Amini (University of Zurich,
Switzerland), Dr. Sina Nassiri (SIB Swiss Institute of
Bioinformatics, Lausanne, Switzerland), Dr. Alexandra Malbon
[University of Zurich, Switzerland, and The Royal (Dick)
School of Veterinary Studies and The Roslin Institute Easter
Bush Campus, Midlothian, United Kingdom], and Dr. Julia
Ettlin (University of Zurich, Switzerland), as well as Dr. Maria
Domenica Moccia and Lennart Opitz (Functional Genomics
Center Zurich, Switzerland) for their invaluable contributions
toward the analysis of CAS from canine mammary carcinomas.
Further, the author thanks the Histology Laboratory of
the Institute of Veterinary Pathology (University of Zurich,
Switzerland) for slide preparation and technical assistance.
REFERENCES
Abadie, J., Nguyen, F., Loussouarn, D., Peña, L., Gama, A., Rieder, N., et al. (2017).
Canine invasive mammary carcinomas as models of human breast cancer. Part
2: immunophenotypes and prognostic significance. Breast Cancer Res. Treat.
167, 459–468. doi: 10.1007/s10549-017-4542-8
Al-Dissi, A. N., Haines, D. M., Singh, B., and Kidney, B. A. (2010).
Immunohistochemical expression of vascular endothelial growth factor and
vascular endothelial growth factor receptor-2 in canine simple mammary gland
adenocarcinomas. Can. Vet. J. 51, 1109–1114.
Amini, P., Ettlin, J., Opitz, L., Clementi, E., Malbon, A., and Markkanen, E. (2017).
An optimised protocol for isolation of RNA from small sections of laser-capture
microdissected FFPE tissue amenable for next-generation sequencing. BMC
Mol. Biol. 18:22. doi: 10.1186/s12867-017-0099-7
Amini, P., Nassiri, S., Ettlin, J., Malbon, A., and Markkanen, E. (2019a). Next-
generation RNA sequencing of FFPE subsections reveals highly conserved
stromal reprogramming between canine and human mammary carcinoma. Dis.
Models Mech. 12:dmm040444. doi: 10.1242/dmm.040444
Amini, P., Nassiri, S., Malbon, A., and Markkanen, E. (2019b). Differential stromal
reprogramming in benign and malignant naturally occurring canine mammary
tumours identifies disease-promoting stromal components. bioRxiv[Preprints]
Anjos Dos, D. S., Vital, A. F., Lainetti, P., de, F., Leis-Filho, A. F., Dalmolin, F., et al.
(2019). Deregulation of VEGFR-2 and PDGFR expression and microvascular
density in a triple-negative model of canine malignant mammary tumors with
lymph node or lung metastasis. Vet. Sci. 6:E3. doi: 10.1177/0300985813503568
Aresu, L., Giantin, M., Morello, E., Vascellari, M., Castagnaro, M., Lopparelli, R.,
et al. (2011). Matrix metalloproteinases and their inhibitors in canine mammary
tumors. BMC Vet. Res. 7:33. doi: 10.1186/1746-6148-7-33
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 December 2019 | Volume 7 | Article 348
fcell-07-00348 December 13, 2019 Time: 16:6 # 9
Markkanen Stromal Reprogramming in Canine Mammary Tumors
Bejerano, G., Pheasant, M., Makunin, I., Stephen, S., Kent, W. J., Mattick, J. S.,
et al. (2004). Ultraconserved elements in the human genome. Science 304,
1321–1325. doi: 10.1126/science.1098119
Belluco, S. (2018). Letter to the Editor. Vet. Pathol. 55, 597–597. doi: 10.1016/j.jcpa.
2012.06.009
Bissell, M. J., and Hines, W. C. (2011). Why don’t we get more cancer? A proposed
role of the microenvironment in restraining cancer progression. Nat. Med. 17,
320–329. doi: 10.1038/nm.2328
Boersma, B. J., Reimers, M., Yi, M., Ludwig, J. A., Luke, B. T., Stephens, R. M., et al.
(2007). A stromal gene signature associated with inflammatory breast cancer.
Int. J. Cancer 122, 1324–1332. doi: 10.1073/pnas.0932692100
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A.
(2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68,
394–424. doi: 10.1016/S0140-6736(15)00135-X
Bulkowska, M., Rybicka, A., Senses, K. M., Ulewicz, K., Witt, K., Szymanska, J.,
et al. (2017). MicroRNA expression patterns in canine mammary cancer show
significant differences between metastatic and non-metastatic tumours. BMC
Cancer 17:728. doi: 10.1186/s12885-017-3751-1
Bundesamt für Statistik, B. (2015). Schweizerischer Krebsbericht 2015. Available
at: www.bfs.admin.ch. https://www.bfs.admin.ch/bfs/de/home/statistiken/
kataloge-datenbanken/medienmitteilungen.assetdetail.40064.html (accessed:
November 8, 2018).
Burstein, H. J., Polyak, K., Wong, J. S., Lester, S. C., and Kaelin, C. M. (2004).
Ductal carcinoma in situ of the breast. N. Engl. J. Med. 350, 1430–1441. doi:
10.1056/NEJMra031301
Bussard, K. M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., and Marini,
F. C. (2016). Tumor-associated stromal cells as key contributors to the
tumormicroenvironment. Breast Cancer Res. 18:84. doi: 10.1186/s13058-016-
0740-2
Carvalho, M. I., Guimarães, M. J., Pires, I., Prada, J., Silva-Carvalho, R., Lopes,
C., et al. (2013). EGFR and microvessel density in canine malignant mammary
tumours. Res. Vet. Sci. 95, 1094–1099. doi: 10.1016/j.rvsc.2013.09.003
Carvalho, M. I., Pires, I., Dias, M., Prada, J., Gregório, H., Lobo, L., et al. (2015a).
Intratumoral CD3+ T-Lymphocytes immunoexpression and?its association
with c-Kit, angiogenesis, and overall survival in malignant canine mammary
tumors. Anal. Cell. Pathol. 2015:920409. doi: 10.1155/2015/920409
Carvalho, M. I., Pires, I., Prada, J., Ferreira, A. F., and Queiroga, F. L. (2015b).
Positive interplay between CD3+ T-lymphocytes and concurrent COX-2/EGFR
expression in canine malignant mammary tumors. Anticancer Res. 35, 2915–
2920.
Carvalho, M. I., Pires, I., Prada, J., Gregório, H., Lobo, L., and Queiroga,
F. L. (2016a). Intratumoral FoxP3 expression is associated with angiogenesis
and prognosis in malignant canine mammary tumors. Vet. Immunol.
Immunopathol. 178, 1–9. doi: 10.1016/j.vetimm.2016.06.006
Carvalho, M. I., Pires, I., Prada, J., Raposo, T. P., Gregório, H., Lobo, L., et al.
(2016b). High COX-2 expression is associated with increased angiogenesis,
proliferation and tumoural inflammatory infiltrate in canine malignant
mammary tumours: a multivariate survival study. Vet. Comp. Oncol. 15, 619–
631. doi: 10.1186/bcr554
Carvalho, M. I., Silva-Carvalho, R., Pires, I., Prada, J., Bianchini, R., Jensen-Jarolim,
E., et al. (2016c). A comparative approach of tumor-associated inflammation in
mammary cancer between humans and dogs. BioMed. Res. Int. 2016:4917387.
doi: 10.1155/2016/4917387
Carvalho, M. I., Pires, I., Prada, J., and Queiroga, F. L. (2011). T-lymphocytic
infiltrate in canine mammary tumours: clinic and prognostic implications.
In vivo 25, 963–969.
Case, A., Brisson, B. K., Durham, A. C., Rosen, S., Monslow, J., Buza, E.,
et al. (2017). Identification of prognostic collagen signatures and potential
therapeutic stromal targets in canine mammary gland carcinoma. PLoS One
12:e0180448. doi: 10.1371/journal.pone.0180448
Casey, T., Bond, J., Tighe, S., Hunter, T., Lintault, L., Patel, O., et al. (2008).
Molecular signatures suggest a major role for stromal cells in development of
invasive breast cancer. Breast Cancer Res. Treat. 114, 47–62. doi: 10.1046/j.1365-
2559.2002.14691.x
Chen, X., and Song, E. (2019). Turning foes to friends: targeting cancer-associated
fibroblasts. Nat. Rev. Drug Discov. 18, 99–115. doi: 10.1038/s41573-018-0004-1
Clemente, M., Pérez-Alenza, M. D., Illera, J. C., and Pena, L. (2010). Histological,
immunohistological, and ultrastructural description of vasculogenic mimicry
in canine mammary cancer. Vet. Pathol. 47, 265–274. doi: 10.1177/
0300985809353167
Clemente, M., Sánchez-Archidona, A. R., Sardón, D., Díez, L., Martín-Ruiz, A.,
Caceres, S., et al. (2013). Different role of COX-2 and angiogenesis in canine
inflammatory and non-inflammatory mammary cancer. Vet. J. 197, 427–432.
doi: 10.1016/j.tvjl.2013.02.009
Damasceno, K. A., Ferreira, E., Estrela-Lima, A., Bosco, Y., Silva, L. P., Barros,
A. L. B., et al. (2016). Relationship between the expression of versican and
EGFR, HER-2, HER-3 and CD44 in matrix-producing tumours in the canine
mammary gland. Histol. Histopathol. 31, 675–688. doi: 10.14670/HH-11-705
de Souza, T. A., de Campos, C. B., De Biasi Bassani Gonçalves, A., Nunes, F. C.,
Monteiro, L. N., de Oliveira Vasconcelos, R., et al. (2018). Relationship between
the inflammatory tumor microenvironment and T different histologic types of
canine mammary tumors. Res. Vet. Sci. 119, 209–214. doi: 10.1016/j.rvsc.2018.
06.012
Diessler, M. E., Castellano, M. C., Portiansky, E. L., Burns, S., and Idiart, J. R.
(2016). Canine mammary carcinomas: influence of histological grade, vascular
invasion, proliferation, microvessel density and VEGFR2 expression on lymph
node status and survival time. Vet. Comp. Oncol. 15, 450–461. doi: 10.1016/j.
rvsc.2013.09.003
Elenbaas, B., and Weinberg, R. A. (2001). Heterotypic signaling between epithelial
tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264, 169–184.
doi: 10.1006/excr.2000.5133
Estrela-Lima, A., Araújo, M. S., Costa-Neto, J. M., Teixeira-Carvalho, A., Barrouin-
Melo, S. M., Cardoso, S. V., et al. (2010). Immunophenotypic features of tumor
infiltrating lymphocytes from mammary carcinomas in female dogs associated
with prognostic factors and survival rates. BMC Cancer 10:256. doi: 10.1186/
1471-2407-10-256
Ettlin, J., Clementi, E., Amini, P., Malbon, A., and Markkanen, E. (2017).
Analysis of gene expression signatures in cancer-associated stroma from canine
mammary tumours reveals molecular homology to human breast carcinomas.
Int. J. Mol. Sci. 18:E1101. doi: 10.3390/ijms18051101
Faustino, A. M. R., van Garderen, E., Schalken, J. A., and Nederbragt, H. (2002).
Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine
mammary tissues. J. Comp. Pathol. 126, 1–8. doi: 10.1053/jcpa.2001.0519
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., et al.
(2008). Stromal gene expression predicts clinical outcome in breast cancer. Nat.
Med. 14, 518–527. doi: 10.1038/nm1764
Finak, G., Sadekova, S., Pepin, F., Hallett, M., Meterissian, S., Halwani, F., et al.
(2006). Gene expression signatures of morphologically normal breast tissue
identify basal-like tumors. Breast Cancer Res. 8:R58. doi: 10.1186/bcr1608
Galon, J., and Bruni, D. (2019). Approaches to treat immune hot, altered and
cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18,
197–218. doi: 10.1038/s41573-018-0007-y
Gardner, H. L., Fenger, J. M., and London, C. A. (2015). Dogs as a model for cancer.
Annu. Rev. Anim. Biosci. 4, 199–222. doi: 10.1146/annurev-animal-022114-
110911
Gilbertson, S. R., Kurzman, I. D., Zachrau, R. E., Hurvitz, A. I., and Black,
M. M. (1983). Canine mammary epithelial neoplasms: biologic implications
of morphologic characteristics assessed in 232 dogs. Vet. Pathol. 20, 127–142.
doi: 10.1177/030098588302000201
Goldschmidt, M., Pena, L., Rasotto, R., and Zappulli, V. (2011). Classification and
grading of canine mammary tumors. Vet. Pathol. 48, 117–131. doi: 10.1080/
01652176.1993.9694381
Gordon, I., Paoloni, M., Mazcko, C., and Khanna, C. (2009). The comparative
oncology trials consortium: using spontaneously occurring cancers in dogs to
inform the cancer drug development pathway. PLoS Med. 6:e1000161. doi:
10.1371/journal.pmed.1000161.g001
Graham, J. C., and Myers, R. K. (1999). The prognostic significance of angiogenesis
in canine mammary tumors. J. Vet. Intern. Med. 13, 416–418. doi: 10.1892/
0891-66401999013<0416:tpsoai<2.3.co;2
Grüntzig, K., Graf, R., Hässig, M., Welle, M., Meier, D., Lott, G., et al. (2015). The
swiss canine cancer registry: a retrospective study on the occurrence of tumours
in dogs in Switzerland from 1955 to 2008. J. Comp. Pathol. 152, 161–171.
doi: 10.1016/j.jcpa.2015.02.005
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 December 2019 | Volume 7 | Article 348
fcell-07-00348 December 13, 2019 Time: 16:6 # 10
Markkanen Stromal Reprogramming in Canine Mammary Tumors
Hanahan, D., and Coussens, L. M. (2012). Accessories to the crime: functionsof
cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322. doi:
10.1016/j.ccr.2012.02.022
Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation.
Cell 144, 646–674. doi: 10.1016/j.cell.2011.02.013
Harvell, D. M. E., Kim, J., O’Brien, J., Tan, A.-C., Borges, V. F., Schedin, P., et al.
(2013). Genomic signatures of pregnancy-associated breast cancer epithelia and
stroma and their regulation by estrogens and progesterone. Horm. Cancer 4,
140–153. doi: 10.1007/s10555-007-9073-z
Hirayama, K., Yokota, H., Onai, R., Kobayashi, T., Kumata, T., Kihara, K., et al.
(2002). Detection of matrix metalloproteinases in canine mammary tumours:
analysis by immunohistochemistry and zymography. J. Comp. Pathol. 127,
249–256. doi: 10.1053/jcpa.2002.0590
Im, K. S., Kim, J. H., Yhee, J. Y., Yu, C. H., Kim, N. H., Nho, W. G., et al. (2011).
Tryptase-positive mast cells correlate with angiogenesis in canine mammary
carcinoma. J. Comp. Pathol. 144, 157–163. doi: 10.1016/j.jcpa.2010.08.006
Im, K. S., Kim, N. H., Lim, H. Y., Kim, H. W., Shin, J. I., and Sur, J. H. (2013).
Analysis of a new histological and molecular-based classification of canine
mammary neoplasia. Vet. Pathol. 51, 549–559. doi: 10.2754/avb200574010103
Kalluri, R. (2016). The biology and function of fibroblasts in cancer. Nat. Rev.
Cancer 16, 582–598. doi: 10.1038/nrc.2016.73
Karlsson, E. K., and Lindblad-Toh, K. (2008). Leader of the pack: gene mapping
in dogs and other model organisms. Nat. Rev. Genet. 9, 713–725. doi: 10.1038/
nrg2382
Kawai, K., Uetsuka, K., Doi, K., and Nakayama, H. (2006). The activity of
matrix metalloproteinases (MMPS) and tissue inhibitors of metalloproteinases
(TIMPs) in mammary tumors of dogs and rats. J. Vet. Med. Sci. 68, 105–111.
doi: 10.1292/jvms.68.105
Kim, J.-H., Chon, S.-K., Im, K.-S., Kim, N.-H., and Sur, J.-H. (2013).
Correlation of tumor-infiltrating lymphocytes to histopathological features and
molecular phenotypes in canine mammary carcinoma: a morphologic and
immunohistochemical morphometric study. Can. J. Vet. Res. 77, 142–149.
Kim, J. H., Hur, J. H., Lee, S. M., Im, K. S., Kim, N. H., and Sur, J. H. (2012).
Correlation of Foxp3 positive regulatory T cells with prognostic factors in
canine mammary carcinomas. Vet. J. 193, 222–227. doi: 10.1016/j.tvjl.2011.10.
022
Klopfleisch, R., Lenze, D., Hummel, M., and Gruber, A. D. (2010). Metastatic
canine mammary carcinomas can be identified by a gene expression profile
that partly overlaps with human breast cancer profiles. BMC Cancer 10:423.
doi: 10.1177/0300985809353310
Klopfleisch, R., Lenze, D., Hummel, M., and Gruber, A. D. (2011). The metastatic
cascade is reflected in the transcriptome of metastatic canine mammary
carcinomas. Vet. J. 190, 236–243. doi: 10.1016/j.tvjl.2010.10.018
Knudsen, E. S., Ertel, A., Davicioni, E., Kline, J., Schwartz, G. F., and Witkiewicz,
A. K. (2012). Progression of ductal carcinoma in situ to invasive breast cancer
is associated with gene expression programs of EMT and myoepithelia. Breast
Cancer Res. Treat. 133, 1009–1024. doi: 10.1007/s10549-011-1894-3
Król, M., Pawłowski, K. M., Majchrzak, K., Dolka, I., Abramowicz, A., Szyszko, K.,
et al. (2011a). Density of tumor-associated macrophages (TAMs) and expression
of their growth factor receptor MCSF-R and CD14 in canine mammary
adenocarcinomas of various grade of malignancy and metastasis. Pol. J. Vet.
Sci. 14, 3–10. doi: 10.1158/0008-5472.CAN-05-4005
Król, M., Pawłowski, K. M., Dolka, I., Musielak, O., Majchrzak, K., Mucha, J., et al.
(2011b). Density of Gr1-positive myeloid precursor cells, p-STAT3 expression
and gene expression pattern in canine mammary cancer metastasis. Vet. Res.
Commun. 35, 409–423. doi: 10.1146/annurev.med.49.1.407
Lahkhani, S. R., Ellis, I. O., Schnitt, S. J., Tan, P. H., and van de Vijver, M. J. (2012).
). WHO Classification of Tumours of the Breast, 4th Edn. Lyon: International
Agency for Research on Cancer.
Lamp, O., Honscha, K. U., Schweizer, S., Heckmann, A., Blaschzik, S., and
Einspanier, A. (2011). The metastatic potential of canine mammary tumours
can be assessed by mRNA expression analysis of connective tissue modulators.
Vet. Comp. Oncol. 11, 70–85. doi: 10.1073/pnas.96.5.1858
Lavalle, G. E., Bertagnolli, A. C., Tavares, W. L. F., and Cassali, G. D. (2009).
Cox-2 expression in canine mammary carcinomas. Vet. Pathol. 46, 1275–1280.
doi: 10.1056/NEJM199101033240101
Levi, M., Brunetti, B., Sarli, G., and Benazzi, C. (2016). Immunohistochemical
expression of P-glycoprotein and breast cancer resistance protein in canine
mammary hyperplasia, neoplasia and supporting stroma. J. Comp. Pathol. 155,
277–285. doi: 10.1016/j.jcpa.2016.07.008
Lim, H. Y., Im, K. S., Kim, N. H., Kim, H. W., Shin, J. I., and Sur, J. H. (2015).
Obesity, expression of adipocytokines, and macrophage infiltration in canine
mammary tumors. Vet. J. 203, 326–331. doi: 10.1016/j.tvjl.2015.01.005
Liu, D., Xiong, H., Ellis, A. E., Northrup, N. C., Dobbin, K. K., Shin, D. M., et al.
(2015). Canine spontaneous head and neck squamous cell carcinomas represent
their human counterparts at the molecular level. PLoS Genet. 11:e1005277.
doi: 10.1371/journal.pgen.1005277.s004
Liu, D., Xiong, H., Ellis, A. E., Northrup, N. C., Rodriguez, C. O., O’Regan, R. M.,
et al. (2014). Molecular homology and difference between spontaneous canine
mammary cancer and human breast cancer. Cancer Res. 74, 5045–5056. doi:
10.1158/0008-5472.CAN-14-0392
Ma, X.-J., Dahiya, S., Richardson, E., Erlander, M., and Sgroi, D. C. (2009). Gene
expression profiling of the tumor microenvironment during breast cancer
progression. Breast Cancer Res. 11:R7. doi: 10.1186/bcr2222
MacEwen, E. G. (1990). Spontaneous tumors in dogs and cats: models for the
study of cancer biology and treatment. Cancer Metastasis Rev. 9, 125–136.
doi: 10.1007/bf00046339
Matos, A. J. F., and Santos, A. A. (2015). Advances in the understanding of the
clinically relevant genetic pathways and molecular aspects of canine mammary
tumours: part 1. Proliferation, apoptosis and DNA repair. Vet. J. 205, 136–143.
doi: 10.1016/j.tvjl.2015.02.004
Merlo, D. F., Rossi, L., Pellegrino, C., Ceppi, M., Cardellino, U., Capurro, C., et al.
(2008). Cancer incidence in pet dogs: findings of the animal tumor registry of
Genoa, Italy. J. Vet. Intern. Med. 22, 976–984. doi: 10.3109/07357900009012210
Millanta, F., Caneschi, V., Ressel, L., Citi, S., and Poli, A. (2010). Expression
of vascular endothelial growth factor in canine inflammatory and non-
inflammatory mammary carcinoma. J. Comp. Pathol. 142, 36–42. doi: 10.1016/
j.jcpa.2009.06.004
Millanta, F., Silvestri, G., Vaselli, C., Citi, S., Pisani, G., Lorenzi, D., et al. (2006).
The role of vascular endothelial growth factor and its receptor Flk-1/KDR in
promoting tumour angiogenesis in feline and canine mammary carcinomas: a
preliminary study of autocrine and paracrine loops. Res. Vet. Sci. 81, 350–357.
doi: 10.1016/j.rvsc.2006.01.007
Monteiro, L. N., Rodrigues, M. A., Gomes, D. A., Salgado, B. S., and Cassali,
G. D. (2018). Tumour-associated macrophages: relation with progression and
invasiveness, and assessment of M1/M2 macrophages in canine mammary
tumours. Vet. J. 234, 119–125. doi: 10.1016/j.tvjl.2018.02.016
Moschetta, M. G., Maschio, L. B., JARDIm-Perassi, B. V., Gelaleti, G. B., Lopes,
J. R., Leonel, C., et al. (2015). Prognostic value of vascular endothelial growth
factor and hypoxia-inducible factor 1α in canine malignant mammary tumors.
Oncol. Rep. 33, 2345–2353. doi: 10.3892/or.2015.3856
Mucha, J., Rybicka, A., Dolka, I., Szymañska, J., Manuali, E., Parzeniecka-Jaworska,
M., et al. (2016). Immunosuppression in dogs during mammary cancer
development. Vet. Pathol. 53, 1147–1153. doi: 10.1038/nrc1586
Nguyen, F., Peña, L., Ibisch, C., Loussouarn, D., Gama, A., Rieder, N., et al. (2017).
Canine invasive mammary carcinomas as models of human breast cancer. Part
1: natural history and prognostic factors. Breast Cancer Res. Treat. 167, 635–648.
doi: 10.1007/s10549-017-4548-2
Paoloni, M., and Khanna, C. (2008). Translation of new cancer treatments from pet
dogs to humans. Nat. Rev. Cancer 8, 147–156. doi: 10.1038/nrc2273
Papparella, S., Restucci, B., Maiolino, P., and De Vico, G. (1997).
Immunohistochemical distribution of type IV collagenase in normal, dysplastic
and neoplastic canine mammary gland. J. Comp. Pathol. 117, 277–282.
doi: 10.1016/s0021-9975(97)80023-0
Papparella, S., Restucci, B., Paciello, O., and Maiolino, P. (2002). Expression of
matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-
MMP) in canine mammary carcinomas. J. Comp. Pathol. 126, 271–276. doi:
10.1053/jcpa.2002.0552
Pena, L., Andrés, P. J. D., Clemente, M., Cuesta, P., and Pérez-Alenza, M. D. (2013).
Prognostic value of histological grading in noninflammatory canine mammary
carcinomas in a prospective study with two-year follow-up. Vet. Pathol. 50,
94–105. doi: 10.1177/0300985810377187
Planche, A., Bacac, M., Provero, P., Fusco, C., Delorenzi, M., Stehle, J.-C., et al.
(2011). Identification of prognostic molecular features in the reactive stroma
of human breast and prostate cancer. PLoS One 6:e18640. doi: 10.1371/journal.
pone.0018640.s006
Frontiers in Cell and Developmental Biology | www.frontiersin.org 10 December 2019 | Volume 7 | Article 348
fcell-07-00348 December 13, 2019 Time: 16:6 # 11
Markkanen Stromal Reprogramming in Canine Mammary Tumors
Qiu, C. W., Lin, D. G., Wang, J. Q., Li, C. Y., and Deng, G. Z. (2008). Expression
and significance of PTEN and VEGF in canine mammary gland tumours. Vet.
Res. Commun. 32, 463–472. doi: 10.1038/sj.onc.1205054
Quail, D. F., and Joyce, J. A. (2013). Microenvironmental regulation of tumor
progression and metastasis. Nat. Med. 19, 1423–1437. doi: 10.1016/j.ccr.2013.
02.013
Queiroga, F. L., Pires, I., Parente, M., Gregório, H., and Lopes, C. S. (2011a). COX-
2 over-expression correlates with VEGF and tumour angiogenesis in canine
mammary cancer. Vet. J. 189, 77–82. doi: 10.1016/j.tvjl.2010.06.022
Queiroga, F. L., Raposo, T., Carvalho, M. I., Prada, J., and Pires, I. (2011b). Canine
mammary tumours as a model to study human breast cancer: most recent
findings. In vivo 25, 455–465.
Raposo, T., Gregório, H., Pires, I., Prada, J., and Queiroga, F. L. (2012). Prognostic
value of tumour-associated macrophages in canine mammary tumours. Vet.
Comp. Oncol. 12, 10–19. doi: 10.1586/erm.10.97
Raposo, T. P., Pires, I., Carvalho, M. I., Prada, J., Argyle, D. J., and Queiroga,
F. L. (2013). Tumour-associated macrophages are associated with vascular
endothelial growth factor expression in canine mammary tumours. Vet. Comp.
Oncol. 13, 464–474. doi: 10.1016/j.trsl.2011.11.005
Rasotto, R., Berlato, D., Goldschmidt, M. H., and Zappulli, V. (2017). Prognostic
significance of canine mammary tumor histologic subtypes. Vet. Pathol. 54,
571–578. doi: 10.1177/0300985817698208
Rasotto, R., Zappulli, V., Castagnaro, M., and Goldschmidt, M. H. (2012). A
retrospective study of those histopathologic parameters predictive of invasion of
the lymphatic system by canine mammary carcinomas. Vet. Pathol. 49, 330–340.
doi: 10.1016/j.canlet.2006.12.036
Reis dos, D. C., Damasceno, K. A., de Campos, C. B., Veloso, E. S., Pêgas, G. R. A.,
Kraemer, L. R., et al. (2019). Versican and tumor-associated macrophages
promotes tumor progression and metastasis in canine and murine models of
breast carcinoma. Front. Oncol. 9:395. doi: 10.1369/0022155411401748
Restucci, B., Borzacchiello, G., Maiolino, P., Martano, M., Paciello, O., and
Papparella, S. (2004). Expression of vascular endothelial growth factor receptor
Flk-1 in canine mammary tumours. J. Comp. Pathol. 130, 99–104. doi: 10.1016/
j.jcpa.2003.07.001
Restucci, B., De Vico, G., and Maiolino, P. (2000). Evaluation of angiogenesis
in canine mammary tumors by quantitative platelet endothelial cell adhesion
molecule immunohistochemistry. Vet. Pathol. 37, 297–301. doi: 10.1354/vp.37-
4-297
Restucci, B., Papparella, S., Maiolino, P., and De Vico, G. (2002). Expression of
vascular endothelial growth factor in canine mammary tumors. Vet. Pathol. 39,
488–493. doi: 10.1354/vp.39-4-488
Rivera, P., and Euler von, H. (2011). Molecular biological aspects on canine
and human mammary tumors. Vet. Pathol. 48, 132–146. doi: 10.1177/
0300985810387939
Rivera, P., Melin, M., Biagi, T., Fall, T., Häggström, J., Lindblad-Toh, K., et al.
(2009). Mammary tumor development in dogs is associated with BRCA1 and
BRCA2. Cancer Res. 69, 8770–8774. doi: 10.1158/0008-5472.CAN-09-1725
Rogers, N. (2015). Canine clues: dog genomes explored in effort to bring human
cancer to heel. Nat. Med. 21, 1374–1375. doi: 10.1038/nm1215-1374
Rowell, J. L., McCarthy, D. O., and Alvarez, C. E. (2011). Dog models of naturally
occurring cancer. Trends Mol. Med. 17, 380–388. doi: 10.1016/j.molmed.2011.
02.004
Saeki, K., Endo, H., Uchida, K., Nishimura, R., Sasaki, N., and Nakagawa, T.
(2012). Significance of tumor-infiltrating immune cells in spontaneous canine
mammary gland tumor: 140 cases. J. Vet. Med. Sci. 74, 227–230. doi: 10.1292/
jvms.11-0118
Sakai, K., Maeda, S., Yamada, Y., Chambers, J. K., Uchida, K., Nakayama, H.,
et al. (2018). Association of tumour-infiltrating regulatory T cells with adverse
outcomes in dogs with malignant tumours. Vet. Comp. Oncol. 16, 330–336.
doi: 10.1111/j.1939-1676.2011.0753.x
Santos, A., Lopes, C., Frias, C., Amorim, I., Vicente, C., Gärtner, F., et al. (2011a).
Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary
tumours: a survival study. Vet. J. 190, 396–402. doi: 10.1016/j.tvjl.2010.
12.003
Santos, A., Lopes, C., Marques, R. M., Amorim, I., Ribeiro, J., Frias, C., et al.
(2011b). Immunohistochemical analysis of urokinase plasminogen activator
and its prognostic value in canine mammary tumours. Vet. J. 189, 43–48.
doi: 10.1016/j.tvjl.2010.05.023
Santos, A., Lopes, C., Gärtner, F., and Matos, A. J. F. (2014). VEGFR-2 expression in
malignant tumours of the canine mammary gland: a prospective survival study.
Vet. Comp. Oncol. 14, e83–e92. doi: 10.7314/APJCP.2012.13.9.4645
Santos, A. A., Lopes, C. C., Marques, R. M., Amorim, I. F., Gärtner, M. F., and
de Matos, A. J. F. (2012). Matrix metalloproteinase-9 expression in mammary
gland tumors in dogs and its relationship with prognostic factors and patient
outcome. Am. J. Vet. Res. 73, 689–697. doi: 10.2460/ajvr.73.5.689
Santos, A. A., Lopes, C. L. C., Ribeiro, J. R., Martins, L. R., Santos, J. C., Amorim,
I. F., et al. (2013). Identification of prognostic factors in caninemammary
malignant tumours: a multivariablesurvival study. BMC Vet. Res. 9:1. doi: 10.
1186/1746-6148-9-1
Santos, A. A., and Matos, A. J. F. (2015). Advances in the understanding of the
clinically relevant genetic pathways and molecular aspects of canine mammary
tumours. Part 2: invasion, angiogenesis, metastasis and therapy. Vet. J. 205,
144–153. doi: 10.1016/j.tvjl.2015.03.029
Santos, A. A. F., Oliveira, J. T., Lopes, C. C. C., Amorim, I. F., Vicente, C. M. F. B.,
Gärtner, F. R. M., et al. (2010). Immunohistochemical expression of vascular
endothelial growth factor in canine mammary tumours. J. Comp. Pathol. 143,
268–275. doi: 10.1016/j.jcpa.2010.04.006
Sappino, A. P., Skalli, O., Jackson, B., Schürch, W., and Gabbiani, G. (1988).
Smooth-muscle differentiation in stromal cells of malignant and non-malignant
breast tissues. Int. J. Cancer 41, 707–712. doi: 10.1002/ijc.2910410512
Schiffman, J. D., and Breen, M. (2015). Comparative oncology: what dogs and other
species can teach us about humans with cancer. Philos. Trans. R. Soc. Lond. B
Biol. Sci. 370:20140231. doi: 10.1098/rstb.2014.0231
Seung, B.-J., Lim, H.-Y., Shin, J.-I., Kim, H.-W., Cho, S.-H., Kim, S.-
H., et al. (2018). CD204-expressing tumor-associated macrophages are
associated with malignant, high-grade, and hormone receptor–negative canine
mammary gland tumors. Vet. Pathol. 55, 417–424. doi: 10.1200/JCO.2006.09.
2775
Simons, M., Gordon, E., and Claesson-Welsh, L. (2016). Mechanisms and
regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17,
611–625. doi: 10.1038/nrm.2016.87
Simpson, P. T., Reis-Filho, J. S., Gale, T., and Lakhani, S. R. (2005). Molecular
evolution of breast cancer. J. Pathol. 205, 248–254. doi: 10.1016/S0002-9440(10)
64180-6
Sleeckx, N., de Rooster, H., Veldhuis Kroeze, E., Van Ginneken, C., and Van
Brantegem, L. (2011). Canine Mammary tumours, an overview. Reprod.
Domest. Anim. 46, 1112–1131. doi: 10.2460/javma.2005.226.1354
Sleeckx, N., Van Brantegem, L., Van den Eynden, G., Fransen, E., Casteleyn, C.,
Van Cruchten, S., et al. (2014). Angiogenesis in canine mammary tumours:
a morphometric and prognostic study. J. Comp. Pathol. 150, 175–183. doi:
10.1016/j.jcpa.2013.09.005
Sorenmo, K. U., Kristiansen, V. M., Cofone, M. A., Shofer, F. S., Breen, A. M.,
Langeland, M., et al. (2009). Canine mammary gland tumours; a histological
continuum from benign to malignant; clinical and histopathological evidence.
Vet. Comp. Oncol. 7, 162–172. doi: 10.1111/j.1532-950X.2007.00351.x
Surowiak, P., Murawa, D., Materna, V., Maciejczyk, A., Pudelko, M., Ciesla,
S., et al. (2007). Occurence of stromal myofibroblasts in the invasive ductal
breast cancer tissue is an unfavourable prognostic factor. Anticancer Res. 27,
2917–2924.
Surowiak, P., Suchocki, S., Gyõrffy, B., Gansukh, T., Wojnar, A., Maciejczyk,
A., et al. (2006). Stromal myofibroblasts in breast cancer: relations between
their occurrence, tumor grade and expression of some tumour markers. Folia
Histochem. Cytobiol. 44, 111–116.
Uva, P., Aurisicchio, L., Watters, J., Loboda, A., Kulkarni, A., Castle, J., et al. (2009).
Comparative expression pathway analysis of human and canine mammary
tumors. BMC Genomics 10:135. doi: 10.1186/1471-2164-10-135
Vargas, A. C., McCart Reed, A. E., Waddell, N., Lane, A., Reid, L. E., Smart,
C. E., et al. (2012). Gene expression profiling of tumour epithelial and stromal
compartments during breast cancer progression. Breast Cancer Res. Treat. 135,
153–165. doi: 10.1007/s10549-012-2123-4
Vinothini, G., Balachandran, C., and Nagini, S. (2009). Evaluation of molecular
markers in canine mammary tumors: correlation with histological grading.
Oncol. Res. Featur. Preclin. Clin. Cancer Therapeut. 18, 193–201. doi: 10.3727/
096504009X12596189659042
Westbury, C. B., Reis-Filho, J. S., Dexter, T., Mahler-Araujo, B., Fenwick,
K., Iravani, M., et al. (2009). Genome-wide transcriptomic profiling of
Frontiers in Cell and Developmental Biology | www.frontiersin.org 11 December 2019 | Volume 7 | Article 348
fcell-07-00348 December 13, 2019 Time: 16:6 # 12
Markkanen Stromal Reprogramming in Canine Mammary Tumors
microdissected human breast tissue reveals differential expression of KIT (c-Kit,
CD117) and oestrogen receptor-α (ERα) in response to therapeutic radiation.
J. Pathol. 219, 131–140. doi: 10.1016/S0360-3016(02)04601-1
World Health Organization (2018). WHO Cancer Facts Sheet. Available at:
http://www.who.int/en/news-room/fact-sheets/detail/cancer (accessed:
October 2019).
Yamashita, M., Ogawa, T., Zhang, X., Hanamura, N., Kashikura, Y., Takamura,
M., et al. (2012). Role of stromal myofibroblasts in invasive breast cancer:
stromal expression of alpha-smooth muscle actin correlates with worse
clinical outcome. Breast Cancer 19, 170–176. doi: 10.1007/s12282-010-
0234-5
Yazhou, C., Wenlv, S., Weidong, Z., and Licun, W. (2004). Clinicopathological
significance of stromal myofibroblasts in invasive ductal carcinoma of the
breast. Tumour Biol. 25, 290–295. doi: 10.1159/000081394
Yokota, H., Kumata, T., Taketaba, S., Kobayashi, T., Moue, H., Taniyama,
H., et al. (2001). High expression of 92 kDa type IV collagenase (matrix
metalloproteinase-9) in canine mammary adenocarcinoma. Biochim. Biophys.
Acta 1568, 7–12. doi: 10.1016/s0304-4165(01)00192-1
Yoshimura, H., Michishita, M., Ohkusu-Tsukada, K., Matsuda, Y., Ishiwata, T.,
Naito, Z., et al. (2014). Cellular sources of tenascin-C in canine mammary
carcinomas. Vet. Pathol. 52, 92–96. doi: 10.1177/0300985810369901
Yoshimura, H., Michishita, M., Ohkusu-Tsukada, K., and Takahashi, K. (2011).
Increased presence of stromal myofibroblasts and tenascin-C with malignant
progression in canine mammary tumors. Vet. Pathol. 48, 313–321. doi: 10.1177/
0300985810369901
Conflict of Interest: The author declares that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Markkanen. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 12 December 2019 | Volume 7 | Article 348
